Privacy Policy

Genentech USA, Inc. ("Genentech") and Novartis Pharmaceuticals Corporation ("Novartis") respects the privacy of our consumers and visitors to this website, and we recognize your need for appropriate protection and management of personal information you share with us (any information by which you can be identified, including but not limited to name, address, e-mail address, and telephone number). We have established this Privacy Policy so that you are informed about how we treat any personally identifiable information that you provide to us in the course of using this website or that we may otherwise collect from or about you in connection with our products and services. This Privacy Policy will inform you of:

  1. How you will be informed of updates to this Privacy Policy
  2. What personally identifiable information of yours we may collect and how we may use this information
  3. Limits on how we would share and disclose your personally identifiable information
  4. Our policy regarding collection of personally identifiable information from minors
  5. How our website uses cookies and similar technologies
  6. Our practices concerning retargeting and interest-based advertising
  7. Our policy regarding browser "do not track" signals
  8. How our website uses social media plugins
  9. Our policy regarding links to third party websites
  10. Security of our website
  11. Additional information for California residents
  12. How you can correct and update your personal information

Please note that this website is directed towards users who reside in the United States of America. It is not our intent to gather personally identifiable information from individuals residing outside the U.S. Your access to and use of the website constitute acceptance of this Privacy Policy and consent to Genentech's and Novartis' collection and use of your information as outlined below.

Privacy Policy Updates

From time to time, Genentech and Novartis may revise this Privacy Policy. Any such changes to this Privacy Policy will be promptly reflected on this page. Genentech and Novartis encourage you to review this Privacy Policy regularly for any changes. Your continued use of this website will be subject to the then-current Privacy Policy. The effective date of this Privacy Policy is April 19, 2021.

Information Collection and Use

You can generally visit our website without revealing any personally identifiable information about yourself. However, to access certain options and services we may ask you to provide certain personally identifiable information, and without providing such personally identifiable information, you may be unable to access certain options and services. The following is personally identifiable information that we may collect from or about you and how we use it:

  • Surveys. Information obtained from you on web surveys, such as contact information (name and shipping address), demographic information (zip code, age level) and medical condition. We may use this personally identifiable information to provide you with information and services for which you have expressed an interest or that you may find useful based on your answers in a survey. Additionally, we may refer to your personally identifiable information to better understand your needs and how we can improve our website.
  • Newsletters. Information obtained from you from your request to subscribe to a newsletter, such as contact information (name and e-mail address). We may use this personally identifiable information to deliver the newsletters that you have elected to receive.
  • Registration. Information obtained from you on registration forms used to process your requests for services and information, such as contact information (name, address, e-mail address), password, username or code, age, date of birth, gender, ethnicity and medical condition. This registration information may also be gathered if you register for certain services via fax or mail. We may use this information to send you a welcoming e-mail to verify your username and password, website updates, special offers, notices regarding relevant medical conditions and treatment, or other information responsive to the data that you provide to us. Additionally, we may refer to your personally identifiable information to better understand your needs and how we can improve our website.
  • E-mail Content to a Friend. Information obtained from you regarding friend or family name and e-mail address, if you elect to use our referral service for sending some of our website content to friends and family. We may use this personally identifiable information to automatically send the friend or family member a one-time e-mail inviting them to visit the website. We may store this information for the sole purpose of sending this one-time e-mail.
  • Other Modes on Collection. Information we collect from or about you in other online or offline contexts, including information submitted during purchases of our Xolair products, interactions with Genentech or Novartis employees, adverse event reporting, or participation in a research study. We use such information for a variety of purposes.

CALIFORNIA RESIDENTS: To learn more about the information we collect from or about you, including how we may use and share it, please see the California Residents | Supplemental Privacy Notice section below.

We may combine the personally identifiable information you share with us through this website with other information we collect from or about you, both online and offline. We may also combine this personally identifiable information with records provided by third parties. We use this consolidated information to help us better design our products, to communicate information to you, to enhance our marketing and research activities, and to facilitate other business functions.

In addition to the purposes described above, any information we collect may also be used for analytics purposes (e.g., evaluating site usage patterns, assessing throughput) so that we can gauge the effectiveness of our programs and improve the usefulness of information presented to users.

Genentech and Novartis are the owners of all information collected on our website. California residents can learn more about information we collect from or about you and how we may use it in the California Residents | Supplemental Privacy Notice section below. 

Sharing and Disclosure

We may provide your personally identifiable information that we collect and the data generated by cookies (discussed below) to a parent, subsidiary or affiliate entity within the Genentech and/or Novartis corporate families, partner entities, and the vendors and service agencies that we may engage to assist us. For example, we may provide your personally identifiable information to an organization in order to complete a service (e.g., send out newsletter e-mails you have requested), to assist us in reviewing the data or to provide marketing or advertising on our behalf.

We will also disclose your personally identifiable information if we reasonably believe we are required to do so by law, regulation, legal process, or other government authority (such as reporting safety information to the Food and Drug Administration); to investigate fraud; to protect your safety or the safety of others; or when we have reason to believe that disclosing this information is necessary to protect our rights or the rights of a third party who may be harmed by your activities.

We may transfer your personally identifiable information to a successor entity of either Genentech or Novartis upon a merger, consolidation or other corporate reorganization in which either Genentech or Novartis participates or to a purchaser of all or a portion of either Genentech's or Novartis' assets; or pursuant to a financing arrangement or co-promotional agreement. Any successor entity shall be bound by terms and conditions reasonably similar to this Privacy Policy.

California residents can learn more about how we may disclose the information we collect from or about you in the California Residents | Supplemental Privacy Notice section below.

Minors

This website is not intended for or designed to attract children under the age of 13. Moreover, we do not knowingly collect any personally identifiable information from anyone under the age of 18 without the consent of a parent or guardian, and you must be 18 years of age or older to submit registration or survey information. Should you believe that a minor of whom you are a parent or guardian has registered, please contact us at privacy.office@gene.com and we will make reasonable efforts to remove all personally identifiable information related to the minor.

Cookies, LSOs, GIF Files, and Other Tracking Technologies

Some of our websites may use cookies, local shared objects (LSOs) and other tracking technologies to identify users who have previously visited so the user is recognized upon return, thereby saving them time while on our website. A cookie is a piece of data stored on the user's hard drive containing information about the user. If a user rejects the cookie, they may still use our website. A cookie may be placed by us, or by vendors or service agencies who work with us or with our partners. Similar to a cookie, a Local Shared Object is a collection of data that a web site running Adobe Flash can place on your hard drive to recognize a repeat visitor and store settings and other information.

Our website and emails we send to you may contain transparent GIF files (also known as "web beacons," "action tags," or "pixel tags") to help manage online advertising. These GIF files are used by us and our ad management partners to recognize when a visitor views a web page or opens an email. This information enables us to learn which emails and advertisements bring users to our website.

If you have provided us with personally identifiable information, e.g., through a registration or a request for certain materials, we may associate this personally identifiable information with information gathered through these tracking technologies. This allows us to offer increased personalization and functionality.

Our website may use Google Analytics, a web analytics service provided by Google, Inc. ("Google"). Google Analytics uses cookies to analyze use patterns and may collect information about your use of  the  website,  including  your  IP  address.  More  information  on  Google  Analytics  can  be  found here: www.google.com/policies/privacy/partners/. If you would like to opt-out of having your data used by Google Analytics, please use the Google Analytics opt-out available here: https://tools.google.com/dlpage/gaoptout/. Other information on opt-outs for targeted advertisement delivery is available below. Please note that Genentech and Novartis make no representations regarding the functionality of Google opt-out mechanisms, and further, opting out of Google Analytics will not preclude the use of your data by other analytics services.

Retargeting and Interest-Based Advertising

We use third party advertising companies to place ads on other websites. These companies may use data about your visits to this and other websites in order to measure advertising effectiveness and to provide advertisements about our goods and services that may be of interest to you. Like most advertisers, we place advertisements where we think they will be most relevant to customers. One way we do so is by allowing network advertising companies with whom we work to place their own cookies when an individual visits our site. This enables the network advertising company to recognize individuals who have previously visited our site. When the individual visits a third-party web site on which that network advertising company has purchased ad space, the advertising company can then recognize the individual’s interest in our products and services and deliver one of our advertisements.

Some of our websites use two Google Analytics Advertising Display Features, which collect information through cookies: Remarketing with Google Analytics and Demographics and Interests reporting.  If you would like to opt-out of having your data used by these cookies, please use the Google Analytics opt-out available here: https://tools.google.com/dlpage/gaoptout/.

The Digital Advertising Alliance maintains a web site where consumers can opt out from receiving interest-based advertising from some or all of the network advertising companies participating in the program ( www.AboutAds.info/choices).

Do-Not-Track Signals and Similar Mechanisms

Some web browsers may transmit "do-not-track" signals to websites with which the browser communicates. This website does not currently respond to these "do-not-track" signals.

Social Media Plugins

Our website may use social media plugins (e.g., the Facebook "Like" button, "Share to Twitter" button) to enable you to easily share information with others. When you visit our website, the operator of the social plugin can place a cookie on your computer, enabling that operator to recognize individuals who have previously visited our site. If you are logged into the social media website (e.g., Facebook, Twitter, Google+) while browsing on our website, the social plugins allow that social media website to receive information that you have visited our website. The social plugins also allow the social media website to share information about your activities on our website with other users of their social media website. For example, Facebook Social Plugins allow Facebook to show your Likes and comments on our pages to your Facebook friends. Facebook Social Plugins also allow you to see your friends' Facebook activity on our website. Neither Genentech nor Novartis control any of the content from the social media plugins. For more information about social plugins from other social media websites, you should refer to those sites' privacy and data sharing statements.

Log Files and Aggregate Information

We may track the total number of visitors to our website, the number of visitors to each page of our website, IP addresses, and the domain names of our users' Internet Service Providers, and we may analyze these data for trends and statistics in the aggregate, but such information will be in aggregate form only and it will not contain personally identifiable data. Such aggregate information is not linked to any personally identifiable information that can identify any individual person.

We may use such aggregate information to analyze trends, administer the website, track user's movement, and gather broad demographic information for aggregate use. We may share this aggregate information with our corporate partners and contracted vendors to assist us in operating the website and to enable them to better understand Genentech's and/or Novartis' businesses.

Links to Third Party Sites

This website may contain links to other websites on the Internet that are not under the control of or maintained by either Genentech or Novartis. Such links do not constitute an endorsement by Genentech or Novartis of those other websites, the content displayed therein, or the persons or entities associated therewith. You acknowledge that Genentech and Novartis are providing these links to you only as a convenience, and you agree that Genentech and Novartis are not responsible for the content of such websites. Your use of these other linked websites is subject to the respective terms of use and privacy policies located on the linked websites.

Security

Genentech, Novartis, and their third-party providers may employ procedural and technological security measures, consistent with industry practice. Such measures are reasonably designed to protect your personally identifiable information from loss, unauthorized access, disclosure, alteration or destruction. Genentech and Novartis may use encryption, password protection, secure socket layers, internal restrictions and other security measures to help prevent unauthorized access to your personally identifiable information . However, you provide your information to us at your own risk. We cannot guarantee that your data will not be lost, accessed without authorization, disclosed, altered, or destroyed.

CALIFORNIA RESIDENTS | Supplemental Privacy Notice

The California Consumer Privacy Act of 2018 (CCPA) gives California residents the right to know what personal information a company has collected about them, including whether it is being sold or disclosed to third-parties, and the right to prevent that company from selling their information. The CCPA also prevents companies from retaliating against consumers for exercising these rights – companies must continue to give consumers who exercise the right to refuse sale of their personal information access to equal products for equal prices. This web site is controlled by Genentech and Novartis, and the personal information collected on this site is sent to both Genentech and Novartis.

        To review Genentech’s Supplemental Privacy Notice for California residents, click here.

        To review Novartis’s Supplemental Privacy Notice for California residents, click here.

Correction/Updating Personally Identifiable Information

Genentech and Novartis are committed to respecting your right to access and correct your personal information. You can call 877-GENENTECH and we will be happy to assist you with your request. You may also "opt out" of receiving e-mails and other communications from us pertaining to the information and content of this website by using the unsubscribe feature included in the e-mails we send. If you have any questions about this online privacy policy or the information practices of this site, you may contact us by email at privacy.office@gene.com or by mail at:

Contacting Genentech

Genentech USA, Inc.

Attn: Privacy Office

1 DNA Way

South San Francisco, CA 94080

History of Recent Updates and Changes to this Privacy Policy

Privacy Policy last updated: April 19, 2021

  • Revised all sections to state that the personally identifiable information a user shares through this website is collected by both Genentech and Novartis.

What is XOLAIR?

XOLAIR® (omalizumab) for subcutaneous use is an injectable prescription medicine used to treat:

  • moderate to severe persistent asthma in people 6 years of age and older whose asthma symptoms are not well controlled with asthma medicines called inhaled corticosteroids. A skin or blood test is performed to see if you have allergies to year-round allergens. It is not known if XOLAIR is safe and effective in people with asthma under 6 years of age.
  • nasal polyps in people 18 years of age and older when medicines to treat nasal polyps called nasal corticosteroids have not worked well enough. It is not known if XOLAIR is safe and effective in people with nasal polyps under 18 years of age.
  • chronic spontaneous urticaria (CSU, previously referred to as chronic idiopathic urticaria (CIU), chronic hives without a known cause) in people 12 years of age and older who continue to have hives that are not controlled with H1 antihistamine treatment. It is not known if XOLAIR is safe and effective in people with CSU under 12 years of age.

XOLAIR is not used to treat other allergic conditions, other forms of hives, or sudden breathing problems.

What is the most important information I should know about XOLAIR? 

Severe allergic reaction. A severe allergic reaction called anaphylaxis can happen when you receive XOLAIR. The reaction can occur after the first dose, or after many doses. It may also occur right after a XOLAIR injection or days later. Anaphylaxis is a life-threatening condition and can lead to death. Go to the nearest emergency room right away if you have any of these symptoms of an allergic reaction:

  • wheezing, shortness of breath, cough, chest tightness, or trouble breathing
  • low blood pressure, dizziness, fainting, rapid or weak heartbeat, anxiety, or feeling of “impending doom”
  • flushing, itching, hives, or feeling warm
  • swelling of the throat or tongue, throat tightness, hoarse voice, or trouble swallowing

Your healthcare provider will monitor you closely for symptoms of an allergic reaction while you are receiving XOLAIR and for a period of time after treatment is initiated. Your healthcare provider should talk to you about getting medical treatment if you have symptoms of an allergic reaction.

Do not receive and use XOLAIR if you are allergic to omalizumab or any of the ingredients in XOLAIR.

Before receiving XOLAIR, tell your healthcare provider about all of your medical conditions, including if you:

  • have a latex allergy or any other allergies (such as food allergy or seasonal allergies). The needle cap on the XOLAIR prefilled syringe contains a type of natural rubber latex.
  • have sudden breathing problems (bronchospasm)
  • have ever had a severe allergic reaction called anaphylaxis
  • have or have had a parasitic infection
  • have or have had cancer
  • are pregnant or plan to become pregnant. It is not known if XOLAIR may harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if XOLAIR passes into your breast milk. Talk with your healthcare provider about the best way to feed your baby while you receive and use XOLAIR.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I receive and use XOLAIR?

  • When starting treatment, XOLAIR should be given by your healthcare provider in a healthcare setting.
  • If your healthcare provider decides that you or a caregiver may be able to give your own XOLAIR prefilled syringe injections, you should receive training on the right way to prepare and inject XOLAIR.
  • Do not try to inject your XOLAIR prefilled syringe until you have been shown the right way to give XOLAIR injections by a healthcare provider. Use XOLAIR exactly as prescribed by your healthcare provider. For children 12 years of age and older, XOLAIR prefilled syringe may be self-injected under adult supervision. For children 6 to 11 years of age, XOLAIR prefilled syringe should be injected by a caregiver.
  • See the detailed Instructions for Use that comes with XOLAIR for information on the right way to prepare and inject XOLAIR.
  • XOLAIR is given in 1 or more injections under the skin (subcutaneous), 1 time every 2 or 4 weeks.
  • In people with asthma and nasal polyps, a blood test for a substance called IgE must be performed before starting XOLAIR to determine the appropriate dose and dosing frequency.
  • In people with chronic hives, a blood test is not necessary to determine the dose or dosing frequency.
  • Do not decrease or stop taking any of your other asthma, nasal polyps, or hive medicine unless your healthcare providers tell you to.
  • You may not see improvement in your symptoms right away after XOLAIR treatment. If your asthma symptoms do not improve or get worse, call your healthcare provider.
  • If you inject more XOLAIR than prescribed, call your healthcare provider right away.

What are the possible side effects of XOLAIR?

XOLAIR may cause serious side effects, including:

  • Cancer. Cases of cancer were observed in some people who received XOLAIR.
  • Inflammation of your blood vessels. Rarely, this can happen in people with asthma who receive XOLAIR. This usually, but not always, happens in people who also take a steroid medicine by mouth that is being stopped or the dose is being lowered. It is not known whether this is caused by XOLAIR. Tell your healthcare provider right away if you have rash; chest pain; shortness of breath; a feeling of pins and needles or numbness of your arms or legs.
  • Fever, muscle aches, and rash. Some people get these symptoms 1 to 5 days after receiving a XOLAIR injection. If you have any of these symptoms, tell your healthcare provider.
  • Parasitic infection. Some people who are at a high risk for parasite (worm) infections, get a parasite infection after receiving XOLAIR. Your healthcare provider can test your stool to check if you have a parasite infection.
  • Heart and circulation problems. Some people who receive XOLAIR have had chest pain, heart attack, blood clots in the lungs or legs, or temporary symptoms of weakness on one side of the body, slurred speech, or altered vision. It is not known whether these are caused by XOLAIR.

The most common side effects of XOLAIR:

  • In adults and children 12 years of age and older with asthma: joint pain especially in your arms and legs, dizziness, feeling tired, itching, skin rash, bone fractures, and pain or discomfort of your ears.
  • In children 6 to less than 12 years of age with asthma: swelling of the inside of your nose, throat, or sinuses, headache, fever, throat infection, ear infection, abdominal pain, stomach infection, and nose bleeds.
  • In adults with nasal polyps: headache, injection site reactions, joint pain, upper abdominal pain, and dizziness.
  • In people with chronic spontaneous urticaria: nausea, headaches, swelling of the inside of your nose, throat or sinuses, cough, joint pain, and upper respiratory tract infection.

These are not all the possible side effects of XOLAIR. Call your doctor for medical advice about side effects.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555 or Novartis Pharmaceuticals Corporation at (888) 669-6682.

Please see full Prescribing Information, including Medication Guide for additional Important Safety Information and Instructions for Use.